Press Releases GlaxoSmithKline plc LIQUIDNET SYSTEMS

Equities

GSK

GB0009252882

Delayed LIQUIDNET SYSTEMS Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-0.40%	-.--%

01:30pm	GSK to Face Trials Over Zantac Cancer Allegations; Shares Tumble Pre-Bell	MT
01:26pm	GSK : Sell rating from JP Morgan	ZD

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer	01:11pm	BU
GSK : Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer	01:05pm	PU
GSK : Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma - Form 6-K	11:13am	PU
Statement: Zantac (ranitidine) litigation - Delaware State Court Daubert Ruling - Form 6-K	11:10am	PU
Statement: Zantac (ranitidine) litigation - Delaware State Court Daubert Ruling \| GSK	09:00am	AQ
Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma \| GSK	08:29am	AQ
GSK : Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma	06-02	PU
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma	06-02	BU
New data at ASCO showcases the transformational potential of GSK's oncology portfolio \| GSK	05-29	AQ
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases - Form 6-K	05-24	PU
New data at ASCO showcases the transformational potential of GSK's oncology portfolio \| GSK	05-24	AQ
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases \| GSK	05-24	AQ
GSK : New data at ASCO showcases the transformational potential of GSK's oncology portfolio	05-23	PU
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases	05-23	PU
GSK announces positive results from phase III severe asthma trials of depemokimab \| GSK	05-21	AQ
GSK : announces positive results from phase III severe asthma trials of depemokimab - Form 6-K	05-21	PU
GSK : completes sale of remaining shares in Haleon - Form 6-K	05-17	PU
GSK : to become a founding partner of Fleming Initiative to fight antimicrobial resistance (AMR)	05-16	PU
GSK : Director/Pdmr Shareholding - Form 6-K	05-14	PU
GSK : BLOCK LISTING SIX MONTHLY RETURN - Form 6-K	05-13	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GSK plc : Back on track

May 03, 2024 at 10:17 am

GSK PLC : Encouraging start to 2024; guidance raised

May 01, 2024 at 04:38 pm